Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a clinical trial.

It is generally believed that Thai people do not suffer from hypovitaminosis D because there is abundant sunlight throughout the year, and that taking vitamin D supplements could result in abnormally high levels of vitamin D.

Clinical Trials.gov NCT01437111, Registered September 19, 2011.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as an open-label and multicenter study.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the participants and staff both knew the treatment.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

Serum 25-hydroxyvitamin D (25(OH)D) and Beta-CrossLaps (β-CTx) levels were measured at baseline and 26 weeks.

What Was Measured

It is generally believed that Thai people do not suffer from hypovitaminosis D because there is abundant sunlight throughout the year, and that taking vitamin D supplements could result in abnormally high levels of vitamin D.

Topics PubMed links to this paper include Alendronate, Bone Density Conservation Agents, Cholecalciferol, Osteoporosis, Thailand and Vitamin D.

The authors tagged it with the keywords Beta-CrossLaps (β-CTx) and Sunlight exposure.

What This Means in Plain Language

The paper is an open-label and multicenter study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 12 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (BMC musculoskeletal disorders), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.